Saltar para: Post [1], Pesquisa e Arquivos [2]

Noticias de Crohn - Copy.png

Resumo na língua original:

An investigational JAK1 inhibitor was effective and reasonably safe in treating patients with refractory Crohn's disease in a mid-stage, dose-ranging trial, a researcher reported here.


Treatment with AbbVie's oral drug ABT-494, now dubbed upadacitinib, for 16 weeks produced clinical remission rates of up to 27% depending on the dose, compared with 11% in a placebo group, said William Sandborn, MD, of the University of California San Diego, during a late-breaker session at Digestive Disease Week.


Ler artigo original


Autoria e outros dados (tags, etc)

publicado às 13:36


  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.